This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This brought the legislative act known as the Medical Marijuana Access and Resources (MMAR) into legislature on July 30 th , 2001 permitted patients access to cannabis for medicinal purposes, from Licensed Producers approved by Health Canada.
Canada has been at the forefront of shaping much of the rhetoric surrounding cannabis since 2001. But this gap restricts patient access to a medicine that can offer relief to a long list of conditions including chronicpain, seizures attributed to epilepsy, as well as mood disorders such as anxiety and depression.
Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). He acknowledges that science still has much to understand about the complex interactions of cannabinoids and terpenes contained in the cannabis plant. There is need for further research.
On July 30 th , 2001, the government brought this into a legislative act known as the Medical Marijuana Access and Resources (MMAR). The cannabis plant is composed of thousands of biologically active molecules which not only include phytocannabinoids, but also include terpenes and flavonoids. Some well researched terpenes include: .
Chronicpain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Only one article appeared in the MJA in 2000 and again in 2001. Conclusions. This offers a more denotative approach to complement the data.
Based on the limited existing evidence, the best cannabis strain for migraines may be a Type II that includes both THC and CBD, and a terpene profile that includes beta-caryophyllene, myrcene, linalool, limonene, bisabolol, humulene or pinene. The study called out pinene, myrcene, and beta-caryophyllene as specifically useful terpenes.
Cannabis contains analgesic or pain-reducing chemical compounds, including cannabinoids like THC and CBN, that can address pain. CBD, another major cannabinoid, can reduce surface and internal inflammation, often a source of some of the pain you may be experiencing. Types of pain that cannabis can address. PMS cramps. ?
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content